普莱卡纳提德改善腹部膨胀和刺激性肠综合征与便秘的肠道症状
Darren M Brenner1, Amol Sharma2, Satish S C Rao2
1Department of Medicine, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Darren.brenner@nm.org.
Digestive diseases and sciences
|April 9, 2024
概括
普莱卡纳提德在患有便秘性刺激性肠综合征 (IBS-C) 的患者中有效降低了胀气和腹部疼痛,特别是那些有中度至严重症状的患者. 治疗还增加了肠道排便的频率,为IBS-C患者提供了显著的缓解.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床试验分析
背景情况:
- 膨胀是被诊断为便秘 (IBS-C) 刺激性肠综合征的个体普遍和令人痛苦的症状.
- 根据症状严重程度了解治疗疗效对于管理IBS-C至关重要.
研究的目的:
- 评估Plecanatide在IBS-C患者中的有效性,特别是分析经历过膨胀强度分层的结果.
- 为了确定plecanatide是否在IBS-C患者的不同程度的膨胀严重程度上提供好处.
主要方法:
- 对组合的第三期临床试验数据的分析,这些数据涉及12周内接受3毫克或安慰剂治疗的IBS-C成年患者.
- 患者在后期被分为轻度 (膨胀评分≤5) 和中度至重度 (膨胀评分>5) 的基线膨胀组.
- 关键的疗效终点包括膨胀,腹痛和完全自发排便 (CSBM) 频率的变化,以及复合响应者分析.
主要成果:
- 与安慰剂相比,普莱卡纳提德显著降低了膨胀严重程度,腹部疼痛,并增加了CSBM频率,在患者中度至严重的基线膨胀与安慰剂相比.
- 在轻度膨胀小组中,普莱卡纳提德改善了腹痛和CSBM频率,尽管膨胀的改善没有达到统计学意义.
- 在接受普莱卡纳提德治疗的患者中,在轻度和中度至重度的膨胀组中,更高比例的患者实现了复合响应状态 (膨胀和腹部疼痛的改善≥30%).
结论:
- 普莱卡纳提德在改善IBS-C患者的关键胃肠道症状,包括胀气和腹痛方面表现出有效性.
- 普莱卡纳提德的治疗益处扩展到经历中度至严重膨胀的患者,这是一个常见且具有挑战性的IBS-C表现.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
161
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
161
01:17Drugs for Treatment of Diarrhea-Predominant IBS
163
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
163
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
159
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
159
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
198
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
198
01:30Inflammatory Bowel Disease II: Crohn's Disease
227
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
227
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
207
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
207